GNHAY लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (23 Dec 2022 @ 20:10):

Stats
आज की मात्रा	200.00
औसत मात्रा	13.00
बाजार मूल्य	0.00
Last Dividend	$0.411 ( 2022-05-12 )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0 (0.00%)

Vifor Pharma AG सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Vifor Pharma AG वित्तीय

Annual	2021
राजस्व:	$1.82B
सकल लाभ:	$1.15B (63.18 %)
EPS:	$0.445

FY	2021
राजस्व:	$1.82B
सकल लाभ:	$1.15B (63.18 %)
EPS:	$0.445

FY	2020
राजस्व:	$1.71B
सकल लाभ:	$1.00B (58.89 %)
EPS:	$1.108

FY	2019
राजस्व:	$1.88B
सकल लाभ:	$1.12B (59.44 %)
EPS:	$0.490

Financial Reports:

No articles found.

Vifor Pharma AG Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Vifor Pharma AG Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 2.49 - No dividend growth expected in the near future

Information

First Dividend	$0.371	2016-05-02
Last Dividend	$0.411	2022-05-12
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	6	--
Total Paid Out	$2.44	--
Avg. Dividend % Per Year	0.00%	--
Score	2.16	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	2.49
Div. Directional Score	6.33	--

Next Divdend (Est)
(2024-10-07)

$0 Estimate 0.00 %

Dividend Stability

0.04 Very Bad

Dividend Score

2.16

Pay Frequency

Sporadic

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for OTC

Symbol	Title	Last dividend	Frequency	Yearly Dividend
OPHLF	Ex Dividend Knight	2023-09-28	Annually	0.00%
CSNVY	Ex Dividend Junior	2023-05-19	Annually	0.00%
TYFG	Ex Dividend Junior	2023-09-28	Quarterly	0.00%
IMPUY	Ex Dividend Junior	2023-09-21	Sporadic	0.00%
AZIHY	Ex Dividend Junior	2023-05-25	Annually	0.00%
RBGLY	Ex Dividend Knight	2023-08-04	Semi-Annually	0.00%
EFGSY	Ex Dividend Knight	2023-05-11	Annually	0.00%
WEGRY	Ex Dividend Knight	2023-10-05	Annually	0.00%
KPLUY	Ex Dividend Junior	2023-05-11	Annually	0.00%
BTVCY	Ex Dividend Junior	2023-06-01	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.145	1.500	7.09	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0520	1.200	8.27	9.92	[0 - 0.3]
returnOnEquityTTM	0.0752	1.500	-0.276	-0.414	[0.1 - 1]
payoutRatioTTM	0.715	-1.000	2.85	-2.85	[0 - 1]
currentRatioTTM	1.914	0.800	5.43	4.34	[1 - 3]
quickRatioTTM	1.013	0.800	8.75	7.00	[0.8 - 2.5]
cashRatioTTM	1.013	1.500	5.49	8.23	[0.2 - 2]
debtRatioTTM	0.115	-1.500	8.08	-10.00	[0 - 0.6]
interestCoverageTTM	22.19	1.000	2.89	2.89	[3 - 30]
operatingCashFlowPerShareTTM	1.622	2.00	9.46	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.949	2.00	9.53	10.00	[0 - 20]
debtEquityRatioTTM	0.168	-1.500	9.33	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.632	1.000	2.80	2.80	[0.2 - 0.8]
operatingProfitMarginTTM	0.109	1.000	9.81	9.81	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.898	1.000	6.12	6.12	[0.2 - 2]
assetTurnoverTTM	0.358	0.800	-0.948	-0.758	[0.5 - 2]
Total Score				10.18

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	42.75	1.000	5.78	0	[1 - 100]
returnOnEquityTTM	0.0752	2.50	-0.177	-0.414	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.949	2.00	9.68	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	1.622	2.00	9.46	10.00	[0 - 30]
payoutRatioTTM	0.715	1.500	2.85	-2.85	[0 - 1]
pegRatioTTM	-2.43	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.289	1.000	5.27	0	[0.1 - 0.5]
Total Score				2.49

Vifor Pharma AG

Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally. The company offers Ferinject/Injectafer, a solution of ferric carboxymaltose used for the treatment of iron deficiency and iron deficiency anemia; Maltofer, an oral iron polymaltose complex for infants, children, adolescents, and pregnant woman with iron deficiency; and Mircera, a long-acting erythropoiesis-stimulating agent (ESA) to treat symptomatic anemia associated with the chronic kidney disease (CKD).It also provides Retacrit, a short-acting ESA; Venofer, an intravenous iron sucrose used in the intravenous treatment of iron deficiency; and Velphoro, a non-calcium, iron-based chewable phosphate binder for the treatment of hyperphosphatemia in adults with CKD undergoing dialysis. In addition, the company offers Rayaldee, an orally administered, extended release formulation of calcifediol for the treatment of secondary hyperparathyroidism in patients with CKD; and Veltassa for the treatment of hyperkalemia in CKD and chronic heart failure patients. Further, it develops Vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of altitude on oxygen availability; Avacopan, an orally-administered, highly selective inhibitor of C5aR1 for the treatment of orphan and rare renal diseases;ANG-3777 for the treatment of transplant-associated acute kidney injury; Difelikefalin for the treatment for chronic kidney disease-associated pruritus; and VIT-2763 to treat beta-thalassemia. Vifor Pharma AG has a strategic partnership with Fresenius Kabi and Zeria Pharmaceutical. The company was founded in 1872 and is headquartered in Sankt Gallen, Switzerland. As of March 22, 2022, Vifor Pharma AG operates as a subsidiary of CSL Behring AG.